NCT00276159 · STUDY IN CONTEXT

Study of Immune Response Modifier in the Treatment of Hematologic Malignancies

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

Stable disease in Non-Hogkin's Lymphoma = disease that does not satisfy complete (complete regression), partial (\> or = 50% reduction) or progressive disease (increase of 25%) by at least a 4-week period. Since Acute Myelogenous Leukemia is not a solid tumor, Complete Response (CR) = \<5% blasts with hematopoietic recovery (absolute neutrophil count \>500) at 4 weeks.

Includes patients receiving at least 12 doses of 852A study drug.

→

secondary · POSTED

Number of patients who received steroids allowing successful continuation of therapy.

Includes patients receiving at least 12 doses of 852A study drug.

→

secondary · POSTED

Measure of Immune Activation With Correlative Laboratory Studies

Analysis not done to sale of agent - unable to perform.

→

secondary · POSTED

Measurement of peak concentrations of 852A to correlate the side effects of tolerability in patients.

Not able to analysis due to sale of agent - unable to perform.

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-acute-lymphoblastic-leukemia
nct id: NCT00276159
trial label: Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 4
harms Count: 1
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-acute-lymphoblastic-leukemia
nct id
NCT00276159
outcome key
om-0000
source section id
NCT00276159-om-0000
source outcome index
0
endpoint
Number of Patients With 852A Response Using Modified Response Evaluation Criteria in Solid Tumors
endpoint definition
Stable disease in Non-Hogkin's Lymphoma = disease that does not satisfy complete (complete regression), partial (\> or = 50% reduction) or progressive disease (increase of 25%) by at least a 4-week period. Since Acute Myelogenous Leukemia is not a solid tumor, Complete Response (CR) = \<5% blasts with hematopoietic recovery (absolute neutrophil count \>500) at 4 weeks.
time origin
Up to Week 12
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Includes patients receiving at least 12 doses of 852A study drug.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-acute-lymphoblastic-leukemia
nct id
NCT00276159
outcome key
om-0001
source section id
NCT00276159-om-0001
source outcome index
1
endpoint
Number of Patients Who Received Steroids
endpoint definition
Number of patients who received steroids allowing successful continuation of therapy.
time origin
Up to Week 12
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Includes patients receiving at least 12 doses of 852A study drug.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-acute-lymphoblastic-leukemia
nct id
NCT00276159
outcome key
om-0002
source section id
NCT00276159-om-0002
source outcome index
2
endpoint
Measure of Immune Activation With Correlative Laboratory Studies
endpoint definition
Measure of Immune Activation With Correlative Laboratory Studies
time origin
Up to Week 12
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Analysis not done to sale of agent - unable to perform.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-acute-lymphoblastic-leukemia
nct id
NCT00276159
outcome key
om-0003
source section id
NCT00276159-om-0003
source outcome index
3
endpoint
Peak Concentrations of 852A
endpoint definition
Measurement of peak concentrations of 852A to correlate the side effects of tolerability in patients.
time origin
Up to Week 12
analysis role
secondary
reporting status
POSTED
data cutoff
Source null
population note
Not able to analysis due to sale of agent - unable to perform.
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-acute-lymphoblastic-leukemia
nct id
NCT00276159
outcome key
om-0000
arm key
OG000
arm label
852A Treatment
regimen
Patients receiving at least 12 doses of 852A.
analyzed count
6
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00276159-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-acute-lymphoblastic-leukemia
nct id
NCT00276159
outcome key
om-0001
arm key
OG000
arm label
852A Treatment
regimen
Patients receiving at least 12 doses of 852A.
analyzed count
6
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00276159-om-0001#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-acute-lymphoblastic-leukemia
nct id
NCT00276159
outcome key
om-0002
arm key
OG000
arm label
852A Treatment
regimen
Patients receiving at least 12 doses of 852A.
analyzed count
0
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00276159-om-0002#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-acute-lymphoblastic-leukemia
nct id
NCT00276159
outcome key
om-0003
arm key
OG000
arm label
852A Treatment
regimen
Patients receiving at least 12 doses of 852A.
analyzed count
0
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00276159-om-0003#groups/OG000

harms

release id
clinical-indications-draft-1
disease state id
ds-acute-lymphoblastic-leukemia
nct id
NCT00276159
harm key
EG000
source section id
NCT00276159-ae
event group key
EG000
event group label
852A Treatment
serious affected
4
serious at risk
6
other affected
4
other at risk
6
frequency threshold
5
collection period
Day 1 of Treatment through Week 12
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice